8-K: Stoke Therapeutics Announces CEO Transition and Reports Full Year 2024 Financial Results

Stoke Therapeutics reports its full year 2024 financial results, announces the transition of CEO Edward Kaye to an advisory role, and appoints Ian F. Smith as Interim CEO.

Summary

• Stoke Therapeutics reported its full year 2024 financial results and announced a CEO transition.
• Edward Kaye will step down as CEO, effective March 19, 2025, and will transition to an advisory role and remain on the Board of Directors.
• Ian F. Smith has been appointed as Interim CEO, effective March 19, 2025.
• Arthur Tzianabos has been appointed Interim Executive Chair of the Board.
• The company's Phase 3 EMPEROR study of zorevunersen for Dravet syndrome is on track to initiate in the second quarter of 2025.
• As of December 31, 2024, Stoke had $246.7 million in cash, cash equivalents, and marketable securities.
• The company anticipates that this, along with $165 million from the Biogen collaboration, will fund operations to mid-2028.
• Revenue for the year ended December 31, 2024, was $36.6 million, compared to $8.8 million for 2023.
• Net loss for the year ended December 31, 2024, was $89.0 million, or $1.65 per share, compared to $104.7 million, or $2.38 per share for 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is making progress with its lead drug candidate, has a strong cash position, and has entered into a significant collaboration with Biogen. The CEO transition is presented as a planned event, and the new leadership is experienced. However, the company is still operating at a loss, and there are inherent risks in drug development.

Positives

• The company has a strong cash position of $246.7 million as of December 31, 2024.
• The Biogen collaboration is expected to provide $165 million in upfront proceeds and eligible cash flows.
• The company anticipates funding operations to mid-2028.
• Revenue increased significantly from $8.8 million in 2023 to $36.6 million in 2024.
• Net loss decreased from $104.7 million in 2023 to $89.0 million in 2024.
• The FDA granted Breakthrough Therapy Designation for zorevunersen for the treatment of Dravet syndrome.
• The Phase 3 EMPEROR study is on track to initiate in Q2 2025.

Negatives

• The company reported a net loss of $89.0 million for the year ended December 31, 2024.
• Research and development expenses increased from $82.2 million in 2023 to $89.1 million in 2024.
• General and administrative expenses increased from $41.3 million in 2023 to $48.8 million in 2024.

Risks

• The company's ability to advance, obtain regulatory approval, and commercialize its product candidates is subject to risks and uncertainties.
• If Biogen were to breach or terminate the collaboration, the company would not obtain the anticipated financial or other benefits.
• The company and Biogen may not be successful in their development of zorevunersen.
• Positive results in a clinical trial may not be replicated in subsequent trials.
• The company's ability to protect its intellectual property is subject to risks.
• The company's ability to fund development activities and achieve development goals through mid-2028 is subject to risks.

Future Outlook

The company anticipates that its cash, cash equivalents, and marketable securities, along with the $165 million upfront payment from the Biogen collaboration, will fund operations to mid-2028. The Phase 3 EMPEROR study of zorevunersen is on track to initiate in the second quarter of 2025.

Management Comments

• Edward Kaye stated that the recent milestones have catalyzed the Dravet community and put the company on track to initiate EMPEROR in the second quarter.
• Edward Kaye believes the potential of zorevunersen to change the course of Dravet syndrome is becoming increasingly recognized.
• Arthur Tzianabos thanked Ed for his invaluable contributions to Stoke over the last seven years.
• Ian F. Smith is deeply committed to Stokes mission and to advancing zorevunersen as a disease-modifying medicine for the treatment of Dravet syndrome.

Industry Context

Stoke's collaboration with Biogen highlights the increasing interest in RNA-based therapies for rare genetic diseases. The focus on Dravet syndrome, a severe form of epilepsy, reflects the unmet need for disease-modifying treatments in this area. The company's TANGO approach represents a novel strategy for restoring protein expression in haploinsufficiency disorders.

Comparison to Industry Standards

• Stoke's approach to treating Dravet syndrome by targeting the underlying genetic cause aligns with the broader industry trend towards precision medicine.
• Companies like Sarepta Therapeutics and Vertex Pharmaceuticals have successfully developed and commercialized therapies for rare genetic diseases, providing a benchmark for Stoke's ambitions.
• The collaboration with Biogen is similar to other partnerships in the biotech industry, where smaller companies leverage the resources and expertise of larger pharmaceutical companies to accelerate drug development and commercialization.
• Solid Biosciences, where Ian F. Smith is Executive Chair, is also focused on developing therapies for genetic diseases, specifically Duchenne muscular dystrophy, providing a potential point of comparison for Stoke's development strategy.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The CEO transition and financial results will likely impact shareholder value.
• Employees: The CEO transition may create uncertainty among employees.
• Patients: The continued development of zorevunersen offers hope for a new treatment for Dravet syndrome.
• Biogen: The collaboration with Stoke represents a strategic investment in RNA-based therapies.

Next Steps

• Initiate the Phase 3 EMPEROR study of zorevunersen in Q2 2025.
• Continue development and commercialization efforts for zorevunersen in collaboration with Biogen.
• Continue the search for a permanent Chief Executive Officer.
• Advance the company's platform to additional disease areas.

Key Dates